+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Japan Nuclear Imaging Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4774937
  • Report
  • June 2020
  • Region: Japan
  • 80 pages
  • Mordor Intelligence
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • ATOX CO. Ltd
  • Bracco Imaging SpA
  • CANON INC.
  • GE HEALTHCARE
  • IBA Radiopharma Solutions
  • Koninklijke Philips NV
  • MORE
Japan Nuclear Imaging market is expected to witness a CAGR of 6.85% during the forecast period. Certain factors that are driving the market growth include the rise in prevalence of cancer and cardiac disorders, increase in technological advancements, growth in the applications of nuclear medicine and imaging.

After being ranked the topmost cause of life-loss in the last century, stroke is now the third-ranked cause of death in Japan, following cancer and heart disease. According to the 2018 article, “Lifestyle and cardiovascular disease in Japan”, the recent trend of rising CHD (coronary heart disease) prevalence among the urban population is a cause for serious concern, as a potential source of forthcoming problems for public health as well as clinical practice in Japan. Moreover, due to the association between lifestyle and CVD (cardiovascular disease), higher sodium, lower calcium, and lower animal protein content in the diet, along with higher alcohol consumption, may account for the higher prevalence of hypertension and higher risk of stroke in the Japanese population than for western population at same BMI levels. According to the latest OECD data, in Japan, patients with end-stage kidney failure (ESKF), often caused by diabetes and hypertension, are the highest in the OECD at 238 per 100,000 population while the average is 101. Thus, the increasing prevalence of cancer, along with certain cardiovascular diseases, is expected to propel the growth of the nuclear imaging market in Japan.

Key Market Trends

Single Photon Emission Computed Tomography Equipment is Expected to Hold a Significant Market Share

As per the scope of the report, SPECT equipment includes planar scintigraphy, stand-alone SPECT, hybrid SPECT/CT equipment along with radioisotopes delivery systems, etc. SPECT significantly differs from other types of radiologic and tomographic imaging modalities, such as CT scan or conventional radiography. In SPECT, rather than passing x-rays through a patient to form an image, the patient is injected with a radiopharmaceutical which then emits radiation in the form of gamma rays or x-rays, which are detected by a gamma camera. Advances in image processing algorithms, innovations in radionuclide and ligands, and the advent of multi-modality imaging systems are driving the market growth for modern SPECT and SPECT/CT devices.

Competitive Landscape

The Japan Nuclear Imaging market is moderately competitive and consists of a few major players. Companies like ATOX CO. Ltd, Bracco Imaging SpA, CANON INC., Fujifilm (FUJIFILM Toyama Chemical Co. Ltd), GE HEALTHCARE, IBA Radiopharma Solutions, JFE Engineering Corporation, Koninklijke Philips NV, Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd), Siemens Healthineers, among others, hold the substantial market share in the Japan Nuclear Imaging market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ATOX CO. Ltd
  • Bracco Imaging SpA
  • CANON INC.
  • GE HEALTHCARE
  • IBA Radiopharma Solutions
  • Koninklijke Philips NV
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Cancer and Cardiac Disorders
4.2.2 Increase in Technological Advancements
4.2.3 Growth in the Applications of Nuclear Medicine and Imaging
4.3 Market Restraints
4.3.1 High Cost of Techniques
4.3.2 Short Half-life of Radiopharmaceuticals
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Product
5.1.1 Equipment
5.1.2 Radioisotope
5.1.2.1 SPECT Radioisotopes
5.1.2.1.1 Technetium-99m (TC-99m)
5.1.2.1.2 Thallium-201 (TI-201)
5.1.2.1.3 Gallium (Ga-67)
5.1.2.1.4 Iodine (I-123)
5.1.2.1.5 Other SPECT Radioisotopes
5.1.2.2 PET Radioisotopes
5.1.2.2.1 Fluorine-18 (F-18)
5.1.2.2.2 Rubidium-82 (RB-82)
5.1.2.2.3 Other PET Radioisotopes
5.2 Application
5.2.1 SPECT Applications
5.2.1.1 Orthopedics
5.2.1.2 Thyroid
5.2.1.3 Cardiology
5.2.1.4 Other SPECT Applications
5.2.2 PET Applications
5.2.2.1 Oncology
5.2.2.2 Cardiology
5.2.2.3 Neurology
5.2.2.4 Other PET Applications

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ATOX CO. Ltd
6.1.2 Bracco Imaging SpA
6.1.3 CANON INC.
6.1.4 Fujifilm (FUJIFILM Toyama Chemical Co. Ltd)
6.1.5 GE HEALTHCARE
6.1.6 IBA Radiopharma Solutions
6.1.7 JFE Engineering Corporation
6.1.8 Koninklijke Philips NV
6.1.9 Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd)
6.1.10 Siemens Healthineers

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ATOX CO. Ltd
  • Bracco Imaging SpA
  • CANON INC.
  • Fujifilm (FUJIFILM Toyama Chemical Co. Ltd)
  • GE HEALTHCARE
  • IBA Radiopharma Solutions
  • JFE Engineering Corporation
  • Koninklijke Philips NV
  • Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd)
  • Siemens Healthineers
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll